We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells Represents LabCorp in $1.2 Billion Acquisition of Chiltern

01 August 2017

Press Contact

Maria Woehr

Public Relations Manager
+1 212 918 6154

New York, 31 July 2017 – Hogan Lovells represented LabCorp, a leading health care diagnostics company, in the acquisition of Chiltern, a specialty contract research organization (CRO) focusing on clinical research services for the pharmaceutical and medical device industries. /p>

The all-cash transaction is expected to close in the fourth quarter of 2017, subject to regulatory approvals and customary closing conditions. Once the transaction is complete, Chiltern will become part of LabCorp’s Covance segment.

Corporate partners Michael Silver and Allen Hicks led the transaction team, which also included Rob Church, Gabi Witt, Natalie Kone and Philip Corser. Other key members of the Hogan Lovells team included Leigh Oliver, Lauren Battaglia, and Alice Wallace-Wright on antitrust matters; Scott McClure, on tax matters; and Michael Applebaum on executive compensation.

Hogan Lovells has advised LabCorp for more than a decade on many of its most significant strategic acquisitions including: Covance, Genzyme Genetics, Pathology Associates Medical Laboratories (PAML), Mount Sinai Health System Clinical Outreach Laboratories, Monogram Biosciences, Medtox, Liposcience and Sequenom.

About Hogan Lovells

Hogan Lovells is a leading global legal practice providing business-oriented legal advice and high-quality service across its exceptional breadth of practices to clients around the world.

“Hogan Lovells” or the “firm” is an international legal practice that includes Hogan Lovells US LLP and Hogan Lovells International LLP. For more information, see www.hoganlovells.com.

###

 
Loading data